Related Experiment Video
Updated: Nov 6, 2025
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
18.4K
Cluster Headache: A Review and Update in Treatment
Himanshu Suri1, Jessica Ailani2
1Department of Neurology, MedStar Georgetown University Hospital, 3800 Reservoir Rd, PHC-7, Washington, DC, 20007, USA. himanshu.suri@medstar.net.
Current Neurology and Neuroscience Reports
|May 5, 2021
Summary
New treatments for cluster headache include neuromodulation devices and monoclonal antibodies. Early intervention is key to reducing attack frequency and improving patient outcomes for this rare neurological condition.
Area of Science:
- Neurology
- Headache Medicine
Background:
- Cluster headache is a severe trigeminal-autonomic cephalalgia with distinct circadian and seasonal patterns.
- Characterized by unilateral, debilitating attacks with ipsilateral autonomic symptoms, it significantly impacts quality of life.
Observation:
- A case presentation highlights a 43-year-old male experiencing severe, nightly headaches with autonomic features, occurring annually during seasonal changes.
- The patient's symptoms, including sharp retro-orbital pain and ptosis, disrupt sleep and have persisted for years.
Findings:
- Treatment advancements for cluster headache now incorporate handheld neuromodulation devices and monoclonal antibodies alongside traditional therapies.
- Galcanezumab is approved for episodic cluster headache, and non-invasive vagal nerve stimulation shows efficacy.
- Routine pituitary imaging may be unnecessary if brain MRI is normal.
Implications:
- Focusing on early intervention in cluster headache management can reduce attack frequency and cycle length, thereby improving patient outcomes.
- Novel therapeutic targets are emerging for this rare but disabling neurological disorder.
- Integrated treatment strategies combining acute, bridging, and preventive therapies are essential.
Related Concept Videos
01:28Angle Closure Glaucoma: Treatment
919
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
919
01:27Open Angle Glaucoma: Treatment
788
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
788
01:25Glaucoma: Overview
1.0K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.0K
01:20Myasthenia Gravis: Overview and Treatment
2.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.3K